University of Pittsburgh, School of Medicine, Pittsburgh, PA 15213, USA.
New Hope Molecular, Pittsburgh, PA 15228, USA.
Psychol Med. 2023 Oct;53(13):6046-6054. doi: 10.1017/S0033291722003233. Epub 2022 Nov 4.
Refractory depression is a devastating condition with significant morbidity, mortality, and societal cost. Approximately 15% of patients with major depressive disorder are refractory to currently available treatments. We hypothesized metabolic abnormalities contributing to treatment refractory depression are associated with distinct findings identifiable in the cerebrospinal fluid (CSF). Our hypothesis was confirmed by a previous small case-controlled study. Here we present a second, larger replication study.
We conducted a case-controlled, targeted, metabolomic evaluation of 141 adolescent and adult patients with well-characterized history of depression refractory to three maximum-dose, adequate-duration medication treatments, and 36 healthy controls. Plasma, urine, and CSF metabolic profiling were performed by coupled gas chromatography/mass spectrometry, and high-performance liquid chromatography, electrospray ionization, tandem mass spectrometry.
Abnormalities were identified in 67 of 141 treatment refractory depression participants. The CSF abnormalities included: low cerebral folate ( = 20), low tetrahydrobiopterin intermediates ( = 11), and borderline low-tetrahydrobiopterin intermediates ( = 20). Serum abnormalities included abnormal acylcarnitine profile ( = 12) and abnormal serum amino acids ( = 20). Eighteen patients presented with two or more abnormal metabolic findings. Sixteen patients with cerebral folate deficiency and seven with low tetrahydrobiopterin intermediates in CSF showed improvement in depression symptom inventories after treatment with folinic acid and sapropterin, respectively. No healthy controls had a metabolite abnormality.
Examination of metabolic disorders in treatment refractory depression identified an unexpectedly large proportion of patients with potentially treatable abnormalities. The etiology of these abnormalities and their potential roles in pathogenesis remain to be determined.
难治性抑郁症是一种具有重大发病率、死亡率和社会成本的破坏性疾病。大约 15%的重性抑郁症患者对现有治疗方法无反应。我们假设导致治疗抵抗性抑郁症的代谢异常与脑脊液 (CSF) 中可识别的不同发现有关。我们的假设在前一项小规模病例对照研究中得到了证实。在这里,我们提出了第二项更大的复制研究。
我们对 141 名有明确病史的青少年和成年抑郁症患者进行了病例对照、靶向、代谢组学评估,这些患者对三种最大剂量、足够疗程的药物治疗均无反应,同时纳入了 36 名健康对照者。通过气相色谱/质谱联用仪和高效液相色谱、电喷雾电离、串联质谱法进行血浆、尿液和 CSF 代谢谱分析。
在 141 名治疗抵抗性抑郁症患者中,有 67 名患者出现了异常。CSF 异常包括:脑叶酸水平低(=20)、四氢生物蝶呤中间产物低(=11)和边缘低四氢生物蝶呤中间产物(=20)。血清异常包括异常酰基肉碱谱(=12)和异常血清氨基酸谱(=20)。18 名患者出现两种或两种以上异常代谢发现。16 名 CSF 中叶酸缺乏的患者和 7 名 CSF 中四氢生物蝶呤中间产物低的患者,分别接受亚叶酸和沙丙蝶呤治疗后,抑郁症状量表均有改善。没有健康对照者存在代谢物异常。
对治疗抵抗性抑郁症代谢紊乱的检查发现,相当大比例的患者存在潜在可治疗的异常。这些异常的病因及其在发病机制中的潜在作用仍有待确定。